The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming ...

In Q4 and full year 2024, Eli Lilly reported revenue of approximately $13.5 billion and $45 billion (up 32% year-over-year), ...

Eli Lilly & Co.'s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

We recently published a list of the 10 Innovative Healthcare Stocks to Watch in 2025. In this article, we are going to take a ...

The company (LLY) said orforglipron showed statistically significant results and a safety profile that was consistent with injectable GLP-1 medicines in the Phase 3 trial. The once-daily treatment ...

We recently published a list of 15 Best Blue Chip Stocks to Buy According to Billionaires. In this article, we are going to ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

Novo Nordisk (NYSE:NVO) is focused on researching, developing, manufacturing, and distributing pharmaceutical products. For ...

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at certain dosages.

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...